Cancer drug repurposed to fight painful, rare skin diseases
NCT ID NCT06545695
Summary
This study is testing if a low dose of an existing cancer drug, erlotinib, can safely reduce the painful skin thickening and scaling caused by rare genetic skin disorders. It will involve 44 adults with confirmed diagnoses of conditions like epidermolytic ichthyosis. The goal is to see if the drug can control the disease by targeting a specific protein pathway in the skin, potentially improving mobility and pain.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR KERATODERMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Dermatology, Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.